Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer

Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Study ID
NCT00544063
Phase
PHASE1
Status
Unknown

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with irinotecan and oxaliplatin in treating patients with metastatic cancer.

Key Dates

Start date
Oct 31, 2006
Status verified
Jul 2009
Primary completion
Dec 31, 2011

Study Design

Enrollment
33 participants (estimated)
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Maximum tolerated dose of capecitabine

Related Studies